{"id":22894,"date":"2023-01-13T23:49:00","date_gmt":"2023-01-13T15:49:00","guid":{"rendered":"https:\/\/flcube.com\/?p=22894"},"modified":"2025-01-24T23:56:15","modified_gmt":"2025-01-24T15:56:15","slug":"lepure-bio-secures-hundreds-of-millions-in-series-c-funding-for-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=22894","title":{"rendered":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion"},"content":{"rendered":"\n

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.<\/p>\n\n\n\n

Company Overview and Strategic Focus<\/strong>
Founded in 2011, LePure Bio has established a strong business layout focusing on Single Use Systems (SUS), filtration, and culture medium consumables. The company has recently acquired QuaCell Biotechnology, Co., Ltd, a culture medium firm based in the Greater Bay Area, further expanding its product portfolio and market reach. This strategic move underscores LePure Bio’s commitment to innovation and growth in the biotech industry.<\/p>\n\n\n\n

Future Outlook<\/strong>
The Series C financing round marks a significant milestone for LePure Bio, positioning the company to accelerate its global expansion and enhance its R&D capabilities. With robust financial backing and a clear strategic vision, LePure Bio is poised to make a meaningful impact in the biotechnology sector. The construction of new R&D centers and the focus on talent recruitment will further solidify the company’s position as a leader in Single Use Systems and related technologies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,20,3288,3289],"class_list":["post-22894","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-finance","tag-lepure-biotech","tag-quacell-biotechnology"],"yoast_head":"\nLePure Bio Secures Hundreds of Millions in Series C Funding for Expansion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=22894\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=22894\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-13T15:49:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-24T15:56:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion\",\"datePublished\":\"2023-01-13T15:49:00+00:00\",\"dateModified\":\"2025-01-24T15:56:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894\"},\"wordCount\":257,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"Finance\",\"LePure Biotech\",\"QuaCell Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22894#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=22894\",\"name\":\"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-01-13T15:49:00+00:00\",\"dateModified\":\"2025-01-24T15:56:15+00:00\",\"description\":\"Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=22894\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=22894#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion - Insight, China's Pharmaceutical Industry","description":"Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=22894","og_locale":"en_US","og_type":"article","og_title":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=22894","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-01-13T15:49:00+00:00","article_modified_time":"2025-01-24T15:56:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=22894#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=22894"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion","datePublished":"2023-01-13T15:49:00+00:00","dateModified":"2025-01-24T15:56:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=22894"},"wordCount":257,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","Finance","LePure Biotech","QuaCell Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=22894#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=22894","url":"https:\/\/flcube.com\/?p=22894","name":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-01-13T15:49:00+00:00","dateModified":"2025-01-24T15:56:15+00:00","description":"Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised \u201chundreds of millions\u201d of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=22894#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=22894"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=22894#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22894"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22894\/revisions"}],"predecessor-version":[{"id":22897,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/22894\/revisions\/22897"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}